Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

SAfeguarding female FERtility -development of human-relevant in vitro tools for reproductive toxicity

Descrizione del progetto

Strumenti in vitro per lo screening delle tossine riproduttive nelle donne

Negli ultimi trent’anni la fertilità è aumentata a livello globale. Le tossine ambientali, spesso presenti nei prodotti di uso quotidiano, sono un noto fattore di rischio. Gli scienziati non hanno gli strumenti per valutare l’impatto delle sostanze chimiche presenti sul mercato europeo sulla fertilità delle donne. Il progetto SAFER, finanziato dal CER, si propone di sfruttare un’ampia biobanca di ovaie, linee di cellule staminali consolidate e tecnologie multiomiche per sviluppare nuovi test che colmino questa lacuna. Il progetto si concentrerà su sostanze chimiche presenti in modo ubiquitario nelle donne e note per ridurre la funzione ovarica, mappando i meccanismi che mediano la tossicità nel tessuto ovarico esposto chimicamente e nelle colture di modelli embrionali derivati da cellule staminali. Tale comprensione sosterrà lo sviluppo di strumenti in vitro per lo screening degli agenti tossici per la riproduzione femminile.

Obiettivo

Chemical health risk assessment has failed to safeguard fertility in women. Women and their oocytes are exposed to pervasive mixtures of human-made chemicals that correlate with reproductive ageing and infertility. Only 0.5% of the chemicals on the European market have been well characterized for health risks, and reproductive toxicity in women is typically not covered due to missing tools. The new European Growth Strategy aims at sustainable growth, zero-pollution and safe chemicals. While the need for increased chemical testing is tangible, there is a movement to phase out animal experiments. This creates a huge challenge to deliver on the vision of a safe and toxic-free environment.

Here, I will develop new high-content assays for reproductive toxicity in women. SAFER is built on my exceptional ovary biobank, established stem cell lines, and multi-omics technologies. Using chemically exposed ovarian tissue and stem cell derived blastoid cultures, SAFER will map mechanisms mediating toxicity by high-resolution epigenetic and transcriptomic analyses. Model chemicals are chosen based on ubiquitous presence in women and significant associations to decreased ovarian function, as shown by my cohort studies. The identified mechanisms will be tailored into reporter genes that I will insert into new immortalized human ovarian cells as well as stem cells, and develop into high-content screening assays. The product of SAFER is novel in vitro tools for screening of female reproductive toxicants.

Taken together, SAFER sets an example for animal-free derivation of assays for chemical safety assessment. SAFER tools will contribute to identification and restriction of chemicals that pose a hazard to women’s health. This is an important step in the global movement towards a non-toxic, safe environment.

Starting a family is a basic human right, and whether to have a child or not should be decided by the prospective parents, not by the chemicals in their environment.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2023-COG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

KAROLINSKA INSTITUTET
Contributo netto dell'UE
€ 2 000 000,00
Indirizzo
NOBELS VAG 5
171 77 STOCKHOLM
Svezia
Regione
Östra Sverige Stockholm Stockholms län
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 2 000 000,00

Beneficiari (1)